Description: Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Home Page: www.molecularpartners.com
Wagistrasse 14
Schlieren,
8952
Switzerland
Phone:
41 44 755 77 00
Officers
Name | Title |
---|---|
Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Exec. VP of Projects & Member of Management Board |
Mr. Andreas Emmenegger E.M.B.A. | Advisor |
Mr. Alexander Zurcher | COO & Member of Management Board |
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA | Chief Medical Officer & Member of Management Board |
Ms. Renate Gloggner | Exec. VP of People & Community and Member of Management Board |
Mr. Daniel Steiner Ph.D. | Sr. VP of Research |
Mr. Seth D. Lewis | Sr. VP of Investor Relations, Communications & Strategy |
Mr. Michael Pitzner | Gen. Counsel, Compliance Officer & Sr. VP of Legal |
Mr. Thomas Schwerzmann | VP of HR |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
Forward PE: | 13.624 |
---|---|
Trailing PE: | 1.8829 |
Price-to-Book MRQ: | 0.8859 |
Price-to-Sales TTM: | 1.1881 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 163 |